1.
2.
3.
4.
5.
6.
7.
8.
9.
Boros, K.; Freemont, T. Physiology of ageing of the musculoskeletal system. Best Pract. Res. Clin. Rheumatol. 2017, 31, 203–217.
[CrossRef] [PubMed]
Pisani, P.; Renna, M.D.; Conversano, F.; Casciaro, E.; Di Paola, M.; Quarta, E.; Muratore, M.; Casciaro, S. Major osteoporotic
fragility fractures: Risk factor updates and societal impact. World J. Orthop. 2016, 7, 171–181. [CrossRef] [PubMed]
Corrado, A.; Cici, D.; Rotondo, C.; Maruotti, N.; Cantatore, F.P. Molecular basis of bone aging. Int. J. Mol. Sci. 2020, 21, 3679.
[CrossRef] [PubMed]
Yang, X.; Wang, G.; Wang, Y.; Zhou, J.; Yuan, H.; Li, X.; Liu, Y.; Wang, B. Histone demethylase KDM7A reciprocally regulates
adipogenic and osteogenic differentiation via regulation of C/EBPalpha and canonical Wnt signalling. J. Cell. Mol. Med. 2019, 23,
2149–2162. [CrossRef]
Rutkovskiy, A.; Stenslokken, K.O.; Vaage, I.J. Osteoblast differentiation at a glance. Med. Sci. Monit. Basic Res. 2016, 22, 95–106.
[CrossRef]
Zhang, X.; Zhao, G.; Zhang, Y.; Wang, J.; Wang, Y.; Cheng, L.; Sun, M.; Rui, Y. Activation of JNK signaling in osteoblasts is
inversely correlated with collagen synthesis in age-related osteoporosis. Biochem. Biophys. Res. Commun. 2018, 504, 771–776.
[CrossRef]
Eriksen, C.G.; Olsen, H.; Husted, L.B.; Sorensen, L.; Carstens, M.; Soballe, K.; Langdahl, B.L. The expression of IL-6 by osteoblasts
is increased in healthy elderly individuals: Stimulated proliferation and differentiation are unaffected by age. Calcif. Tissue Int.
2010, 87, 414–423. [CrossRef]
Becerikli, M.; Jaurich, H.; Schira, J.; Schulte, M.; Dobele, C.; Wallner, C.; Abraham, S.; Wagner, J.M.; Dadras, M.; Kneser, U.; et al.
Age-dependent alterations in osteoblast and osteoclast activity in human cancellous bone. J. Cell. Mol. Med. 2017, 21, 2773–2781.
[CrossRef]
Awasthi, H.; Mani, D.; Singh, D.; Gupta, A. The underlying pathophysiology and therapeutic approaches for osteoporosis. Med.
Res. Rev. 2018, 38, 2024–2057. [CrossRef]
Nanomaterials 2022, 12, 1680
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
10 of 11
Corrado, A.; Sanpaolo, E.R.; Di Bello, S.; Cantatore, F.P. Osteoblast as a target of anti-osteoporotic treatment. Postgrad. Med. 2017,
129, 858–865. [CrossRef]
McClung, M.R.; Lewiecki, E.M.; Cohen, S.B.; Bolognese, M.A.; Woodson, G.C.; Moffett, A.H.; Peacock, M.; Miller, P.D.; Lederman,
S.N.; Chesnut, C.H.; et al. Bone Loss Study Group. N. Engl. J. Med. 2006, 354, 821–831. [CrossRef] [PubMed]
Diedhiou, D.; Cuny, T.; Sarr, A.; Norou Diop, S.; Klein, M.; Weryha, G. Efficacy and safety of denosumab for the treatment of
osteoporosis: A systematic review. Ann. Endocrinol. 2015, 76, 650–657. [CrossRef] [PubMed]
Canalis, E. Wnt signalling in osteoporosis: Mechanisms and novel therapeutic approaches. Nat. Rev. Endocrinol. 2013, 10, 575–583.
[CrossRef] [PubMed]
Miller, S.A.; St Onge, E.L.; Whalen, K.L. Romosozumab: A novel agent in the treatment for postmenopausal osteoporosis. J. Pharm.
Technol. 2021, 37, 45–52. [CrossRef]
Quemener, A.M.; Bachelot, L.; Forestier, A.; Donnou-Fournet, E.; Gilot, D.; Galibert, M.D. The powerful world of antisense
oligonucleotides: From bench to bedside. Wiley Interdiscip. Rev. RNA 2020, 11, e1594. [CrossRef]
Wang, T.; Chen, C.; Larcher, L.M.; Barrero, R.A.; Veedu, R.N. Three decades of nucleic acid aptamer technologies: Lessons learned,
progress and opportunities on aptamer development. Biotechnol. Adv. 2019, 37, 28–50. [CrossRef]
Nigar, S.; Shimosato, T. Cooperation of oligodeoxynucleotides and synthetic molecules as enhanced immune modulators. Front.
Nutr. 2019, 6, 140. [CrossRef]
Yang, G.; Wan, M.; Zhang, Y.; Sun, L.; Sun, R.; Hu, D.; Zhou, X.; Wang, L.; Wu, X.; Wang, L.; et al. Inhibition of a C-rich
oligodeoxynucleotide on activation of immune cells in vitro and enhancement of antibody response in mice. Immunology 2010,
131, 501–512. [CrossRef]
Feng, Z.; Shen, Y.; Wang, L.; Cheng, L.; Wang, J.; Li, Q.; Shi, W.; Sun, X. An oligodeoxynucleotide with promising modulation
activity for the proliferation and activation of osteoblast. Int. J. Mol. Sci. 2011, 12, 2543–2555. [CrossRef]
Shen, Y.; Feng, Z.; Lin, C.; Hou, X.; Wang, X.; Wang, J.; Yu, Y.; Wang, L.; Sun, X. An oligodeoxynucleotide that induces
differentiation of bone marrow mesenchymal stem cells to osteoblasts in vitro and reduces alveolar bone loss in rats with
periodontitis. Int. J. Mol. Sci. 2012, 13, 2877–2892. [CrossRef]
Yu, W.; Zheng, Y.; Li, H.; Lin, H.; Chen, Z.; Tian, Y.; Chen, H.; Zhang, P.; Xu, X.; Shen, Y. The Toll-like receptor ligand, CpG
oligodeoxynucleotides, regulate proliferation and osteogenic differentiation of osteoblast. J. Orthop. Surg. Res. 2020, 15, 327.
[CrossRef] [PubMed]
Hou, X.; Shen, Y.; Zhang, C.; Zhang, L.; Qin, Y.; Yu, Y.; Wang, L.; Sun, X. A specific oligodeoxynucleotide promotes the
differentiation of osteoblasts via ERK and p38 MAPK pathways. Int. J. Mol. Sci. 2012, 13, 7902–7914. [CrossRef] [PubMed]
Nigar, S.; Yamamoto, Y.; Okajima, T.; Shigemori, S.; Sato, T.; Ogita, T.; Shimosato, T. Synergistic oligodeoxynucleotide strongly
promotes CpG-induced interleukin-6 production. BMC Immunol. 2017, 18, 44. [CrossRef]
Shinji, S.; Umezawa, K.; Nihashi, Y.; Nakamura, S.; Shimosato, T.; Takaya, T. Identification of the myogenetic oligodeoxynucleotides (myoDNs) that promote differentiation of skeletal muscle myoblasts by targeting nucleolin. Front. Cell Dev. Biol. 2021,
8, 616706. [CrossRef] [PubMed]
Nakamura, S.; Yonekura, S.; Shimosato, T.; Takaya, T. Myogenetic oligodeoxynucleotide (myoDN) recovers the differentiation of
skeletal muscle myoblasts deteriorated by diabetes mellitus. Front. Physiol. 2021, 12, 679152. [CrossRef] [PubMed]
Nihashi, Y.; Shinji, S.; Umezawa, K.; Shimosato, T.; Ono, T.; Kagami, H.; Takaya, T. Myogenetic oligodeoxynucleotide complexed
with berberine promotes differentiation of chicken myoblasts. Anim. Sci. J. 2021, 92, e13597. [CrossRef]
Nihashi, Y.; Yamamoto, M.; Shimosato, T.; Takaya, T. Myogenetic oligodeoxynucleotide restores differentiation and reverses
inflammation of myoblasts aggravated by cancer-conditioned medium. bioRxiv 2021, 469038. [CrossRef]
Nohira, N.; Shinji, S.; Nakamura, S.; Nihashi, Y.; Shimosato, T.; Takaya, T. Myogenetic oligodeoxynucleotides as anti-nucleolin
aptamers inhibit the growth of embryonal rhabdomyosarcoma cells. bioRxiv 2021, 464889. [CrossRef]
Macke, T.J.; Case, D.A. Modeling unusual nucleic acid structures. In Molecular Modeling of Nucleic Acids; Leontis, N.B., SantaLucia,
J., Eds.; American Chemical Society: Washington, DC, USA, 1998; pp. 379–393.
Ikebe, J.; Umezawa, K.; Kamiya, N.; Sugihara, T.; Yonezawa, Y.; Takano, Y.; Nakamura, H.; Higo, J. Theory for trivial trajectory
parallelization of multicanonical molecular dynamics and application to a polypeptide in water. J. Comput. Chem. 2011, 32,
1286–1297. [CrossRef]
Maier, J.A.; Matinez, C.; Kasavajhala, K.; Wickstrom, L.; Hauser, K.E.; Simmerling, C. ff14SB: Improving the accuracy of protein
side chain and backbone parameters from ff99SB. J. Chem. Theory Comput. 2015, 11, 3696–3713. [CrossRef]
Tsui, V.; Case, D.A. Theory and applications of the generalized Born solvation model in macromolecular simulations. Biopolymers
2000, 56, 275–291. [CrossRef]
Pohar, J.; Lainscek, D.; Fukui, R.; Yamamoto, C.; Miyake, K.; Jerala, R.; Bencina, M. Species-specific minimal sequence motif for
oligodeoxyribonucleotides activating mouse TLR9. J. Immunol. 2015, 195, 4396–4405. [CrossRef] [PubMed]
Sackesen, C.; van de Veen, W.; Akdis, M.; Soyer, O.; Zumkehr, J.; Ruckert, B.; Stanic, B.; Kalayci, O.; Alkan, S.S.; Gursel, I.; et al.
Suppression of B-cell activation and IgE, IgA, IgG1 and IgG4 production by mammalian telomeric oligonucleotides. Allergy 2013,
68, 593–603. [CrossRef] [PubMed]
Komori, T. Regulation of osteoblast differentiation by Runx2. Adv. Exp. Med. Biol. 2010, 658, 43–49.
Moser, S.C.; van der Eerden, B.C.J. Osteocalcin: A versatile bone-derived hormone. Front. Endocrinol. 2018, 9, 794. [CrossRef]
[PubMed]
Nanomaterials 2022, 12, 1680
37.
38.
39.
40.
41.
42.
43.
44.
45.
46.
47.
48.
49.
50.
51.
11 of 11
Liu, T.M.; Lee, E.H. Transcriptional regulatory cascades in Runx2-dependent bone development. Tissue Eng. Part B Rev. 2013, 19,
254–263. [CrossRef] [PubMed]
Vollmer, J.; Krieg, A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009,
61, 195–2004. [CrossRef]
Nemoto, E.; Honda, T.; Kanaya, S.; Takada, H.; Shimauchi, H. Expression of functional Toll-like receptors and nucleotide-binding
oligomerization domain proteins in murine cementoblasts and their upregulation during cell differentiation. J. Periodontal Res.
2008, 43, 585–593. [CrossRef]
Charles, J.F.; Nakamura, M.C. Bone and the innate immune system. Curr. Osteoporos. Rep. 2014, 12, 1–8. [CrossRef]
El-Sayed, K.M.F.; Boeckler, J.; Dorfer, C.E. TLR expression profile of human alveolar bone proper-derived stem/progenitor cells
and osteoblasts. J. Craniomaxillofac. Surg. 2017, 45, 2054–2060. [CrossRef]
Amcheslavsky, A.; Bar-Shavit, Z. Toll-like receptor 9 ligand blocks osteoclast differentiation through induction of phosphatase.
J. Bone Miner. Res. 2007, 22, 1301–1310. [CrossRef] [PubMed]
Vimalraj, S.; Arumugam, B.; Miranda, P.J.; Selvamurugan, N. Runx2: Structure, function, and phosphorylation in osteoblast
differentiation. Int. J. Biol. Macromol. 2015, 78, 202–208. [CrossRef] [PubMed]
Artigas, N.; Urena, C.; Rodriguez-Carballo, E.; Rosa, J.L.; Ventura, F. Mitogen-activated protein kinase (MAPK)-regulated
interactions between Osterix and Runx2 are critical for the transcriptional osteogenic program. J. Biol. Chem. 2014, 289,
27105–27117. [CrossRef] [PubMed]
Deng, H.; Kuang, P.; Cui, H.; Luo, Q.; Liu, H.; Lu, Y.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; et al. Sodium fluoride induces apoptosis in
mouse splenocytes by activating ROS-dependent NF-κB signaling. Oncotarget 2017, 8, 114428–114441. [CrossRef] [PubMed]
Tian, Y.; Xu, Y.; Fu, Q.; Dong, Y. Osterix is required for Sonic hedgehog-induced osteoblastic MC3T3-E1 cell differentiation. Cell
Biochem. Biophys. 2012, 64, 169–176. [CrossRef] [PubMed]
Takayama, T.; Dai, J.; Tachi, K.; Shohara, R.; Kasai, H.; Imamura, K.; Yamano, S. The potential of stromal cell-derived factor-1
delivery using a collagen membrane for bone regeneration. J. Biomater. Appl. 2017, 31, 1049–1061. [CrossRef]
Gao, J.; Feng, Z.; Wang, X.; Zeng, M.; Liu, J.; Han, S.; Xu, J.; Chen, L.; Cao, K.; Long, J.; et al. SIRT3/SOD2 maintains osteoblast
differentiation and bone formation by regulating mitochondrial stress. Cell Death Differ. 2018, 25, 229–240. [CrossRef]
Lee, D.J.; Tseng, H.C.; Wong, S.W.; Wang, Z.; Deng, M.; Ko, C.C. Dopaminergic effects on in vitro osteogenesis. Bone Res. 2015,
3, 15020. [CrossRef]
Veazey, K.J.; Colding, M.C. Selection of stable reference genes for quantitative rt-PCR comparisons of mouse embryonic and
extra-embryonic stem cells. PLoS ONE 2011, 6, e27592. [CrossRef]
Nihashi, Y.; Miyoshi, M.; Umezawa, K.; Shimosato, T.; Takaya, T. Identification of a novel osteogenetic oligodeoxynucleotide
(osteoDN) that promotes osteoblast differentiation in a TLR9-independent manner. bioRxiv 2022, 485101. [CrossRef]
...
論文の公開元へ
